TY - JOUR
T1 - Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada
T2 - a collaboration of cohort studies
AU - North American AIDS Cohort Collaboration on Research and Design
AU - Althoff, Keri N.
AU - Gebo, Kelly A.
AU - Moore, Richard D.
AU - Boyd, Cynthia M.
AU - Justice, Amy C.
AU - Wong, Cherise
AU - Lucas, Gregory M.
AU - Klein, Marina B.
AU - Kitahata, Mari M.
AU - Crane, Heidi
AU - Silverberg, Michael J.
AU - Gill, M. John
AU - Mathews, William Christopher
AU - Dubrow, Robert
AU - Horberg, Michael A.
AU - Rabkin, Charles S.
AU - Klein, Daniel B.
AU - Lo Re, Vincent
AU - Sterling, Timothy R.
AU - Desir, Fidel A.
AU - Lichtenstein, Kenneth
AU - Willig, James
AU - Rachlis, Anita R.
AU - Kirk, Gregory D.
AU - Anastos, Kathryn
AU - Palella, Frank J.
AU - Thorne, Jennifer E.
AU - Eron, Joseph
AU - Jacobson, Lisa P.
AU - Napravnik, Sonia
AU - Achenbach, Chad
AU - Mayor, Angel M.
AU - Patel, Pragna
AU - Buchacz, Kate
AU - Jing, Yuezhou
AU - Gange, Stephen J.
N1 - Funding Information:
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US Centers for Disease Control and Prevention. KNA was supported by K01AI093197 , National Institute of Allergy and Infectious Diseases, National Institutes of Health . Additionally, this work was supported by National Institutes of Health grants U01AI069918 , F31AI124794 , F31DA037788 , G12MD007583 , K01AI093197 , K23EY013707 , K24AI065298 , K24AI118591 , K24DA000432 , K24DA035684 , KL2TR000421 , M01RR000052 , N01CP01004 , N02CP055504 , N02CP91027 P30AI027757 , P30AI027763 , P30AI027767 , P30AI036219 , P30AI050410 , P30AI094189 , P30AI110527 , P30MH62246 , R01AA016893 , R01CA165937 , R01DA011602 , R01DA012568 , R01AG053100 , R01DA026770 , R24AI067039 , R24AG044325 , U01AA013566 , U01AA020790 , U01AI031834 , U01AI034989 , U01AI034993 , U01AI034994 , U01AI035004 , U01AI035039 , U01AI035040 , U01AI035041 , U01AI035042 , U01AI037613 , U01AI037984 , U01AI038855 , U01AI038858 , U01AI042590 , U01AI068634 , U01AI068636 , U01AI069432 , U01AI069434 , U01AI103390 , U01AI103397 , U01AI103401 , U01AI103408 , U01DA03629 , U01DA036935 , U01HD032632 , U10EY008057 , U10EY008052 , U10EY008067 , U24AA020794 , U54MD007587 , UL1RR024131 , UL1TR000004 , UL1TR000083 , UL1TR000454 , UM1AI035043 , Z01CP010214 , and Z01CP010176 ; contracts CDC-200–2006–18797 and CDC-200–2015–63931 from the US Centers for Disease Control and Prevention ; contract 90047713 from the AHRQ; contract 90051652 from the HRSA; grants CBR-86906, CBR-94036, HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada. Additional support was provided by the National Cancer Institute, National Institute for Mental Health, National Institute on Drug Abuse, the Johns Hopkins Center for AIDS Research (P30 AI094189), and the Sidney Kimmel Comprehensive Cancer Center research programme grant ( P30 CA006973 ).
Funding Information:
KNA, RDM, ACJ, GML, MMK, HC, MJS, MJG, RD, VLR, TRS, FAD, JW, GDK, KA, FJP, JET, JE, LPJ, SN, CA, and SJG report grants from the National Institutes of Health during the conduct of the study and outside the submitted work. KNA also reports personal fees from Trio Health outside of the submitted work. KAG reports grants from Agency for Healthcare Research and Quality (AHRQ; USA) and Health Resources and Services Administration (HRSA; USA) during the conduct of the study, and personal fees from the US Government outside the submitted work. RDM also reports grants from AHRQ and HRSA during the conduct of the study, and personal fees from Medscape LLC outside the submitted work. CMB reports royalties from Up To Date outside of the submitted work. MBK reports funding from the Canadian Institutes of Health Research (CIHR), The CIHR Canadian HIV Trials Network, and le Réseau sida et maladies infectieuses du Fonds de rescherche Santé Québec, for investigator-initiated trials from ViiV Healthcare and Gilead Sciences and personal fees from ViiV Healthcare and Merck, outside the submitted work. HC also reports personal fees from ViiV outside the submitted work. MJS also reports grants from Merck and Gilead outside the submitted work. MJG also reports personal fees from Merck, ViiV Healthcare, and Gilead outside the submitted work. ARR reports grants from Ontario HIV Treatment Network during the conduct of the study, and grants from Merck Frostt, ViiV Healthcare, Gilead Sciences, and Janssen outside the submitted work. FJP also reports personal fees from Merck, ViiV Healthcare, Gilead Sciences, and Janssen, outside the submitted work. JET also reports grants from Allergan and personal fees from AbbVie, Santen, and Gilead outside the submitted work. MAH reports grants from Merck and Gilead outside the submitted work. JE also reports grants from Janssen, ViiV Healthcare, Gilead Sciences, and personal fees from Janssen, Gilead Sciences, ViiV Healthcare, and Merck outside the submitted work. CA also reports grants Gilead and personal fees from ViiV outside of the submitted work. CW, WCM, DBK, CSR, KL, AMM, PP, KB, and YJ have nothing to disclose.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Background: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes. Methods: We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outcomes. Traditional risk factors were tobacco smoking, hypertension, elevated total cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus infections. HIV-related risk factors were low CD4 count (<200 cells per μL), detectable plasma HIV RNA (>400 copies per mL), and history of a clinical AIDS diagnosis. PAFs and 95% CIs were estimated to quantify the proportion of outcomes that could be avoided if the risk factor was prevented. Findings: In each of the study populations for the four outcomes (1405 of 61 500 had non-AIDS-defining cancer, 347 of 29 515 had myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% were men. Preventing smoking would avoid 24% (95% CI 13–35) of these cancers and 37% (7–66) of the myocardial infarctions. Preventing elevated total cholesterol and hypertension would avoid the greatest proportion of myocardial infarctions: 44% (30–58) for cholesterol and 42% (28–56) for hypertension. For liver disease, the PAF was greatest for hepatitis C infection (33%; 95% CI 17–48). For renal disease, the PAF was greatest for hypertension (39%; 26–51) followed by elevated total cholesterol (22%; 13–31), detectable HIV RNA (19; 9–31), and low CD4 cell count (13%; 4–21). Interpretation: The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the importance of screening for these risk factors, improving the effectiveness of prevention (or modification) of these risk factors, and creating sustainable care models to implement such interventions during the decades of life of adults living with HIV who are receiving care. Funding: National Institutes of Health, US Centers for Disease Control and Prevention, the US Agency for Healthcare Research and Quality, the US Health Resources and Services Administration, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long Term Care, and the Government of Alberta.
AB - Background: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes. Methods: We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outcomes. Traditional risk factors were tobacco smoking, hypertension, elevated total cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus infections. HIV-related risk factors were low CD4 count (<200 cells per μL), detectable plasma HIV RNA (>400 copies per mL), and history of a clinical AIDS diagnosis. PAFs and 95% CIs were estimated to quantify the proportion of outcomes that could be avoided if the risk factor was prevented. Findings: In each of the study populations for the four outcomes (1405 of 61 500 had non-AIDS-defining cancer, 347 of 29 515 had myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% were men. Preventing smoking would avoid 24% (95% CI 13–35) of these cancers and 37% (7–66) of the myocardial infarctions. Preventing elevated total cholesterol and hypertension would avoid the greatest proportion of myocardial infarctions: 44% (30–58) for cholesterol and 42% (28–56) for hypertension. For liver disease, the PAF was greatest for hepatitis C infection (33%; 95% CI 17–48). For renal disease, the PAF was greatest for hypertension (39%; 26–51) followed by elevated total cholesterol (22%; 13–31), detectable HIV RNA (19; 9–31), and low CD4 cell count (13%; 4–21). Interpretation: The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the importance of screening for these risk factors, improving the effectiveness of prevention (or modification) of these risk factors, and creating sustainable care models to implement such interventions during the decades of life of adults living with HIV who are receiving care. Funding: National Institutes of Health, US Centers for Disease Control and Prevention, the US Agency for Healthcare Research and Quality, the US Health Resources and Services Administration, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long Term Care, and the Government of Alberta.
UR - http://www.scopus.com/inward/record.url?scp=85060918980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060918980&partnerID=8YFLogxK
U2 - 10.1016/S2352-3018(18)30295-9
DO - 10.1016/S2352-3018(18)30295-9
M3 - Article
C2 - 30683625
AN - SCOPUS:85060918980
SN - 2352-3018
VL - 6
SP - e93-e104
JO - The Lancet HIV
JF - The Lancet HIV
IS - 2
ER -